Nature Reviews Drug Discovery Q1 Unclaimed

Nature Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition to the highest-quality reviews and perspectives covering a broad scope, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers, and concise updates on the latest advances in areas such as new drug approvals, patent law and emerging industry trends and strategies. It has an SJR impact factor of 9,921.

Nature Reviews Drug Discovery focuses its scope in these topics and keywords: drug, strategies, drugs, clinical, antibodies, cancer, human, therapeutic, court, competitioncombating, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Non Open Access

Type of publications:

Publication frecuency: -

Price

- €

Gold OA

-

Green OA

0 €

Non OA

Metrics

Nature Reviews Drug Discovery

9,921

SJR Impact factor

328

H Index

247

Total Docs (Last Year)

676

Total Docs (3 years)

7946

Total Refs

8550

Total Cites (3 years)

314

Citable Docs (3 years)

12,38

Cites/Doc (2 years)

32,17

Ref/Doc

Aims and Scope


drug, strategies, drugs, clinical, antibodies, cancer, human, therapeutic, court, competitioncombating, cureupcoming, deconvolution, directionspde, discovery, discoverycan, disease, diseasesflipping, class, catalysts, candidateserratum, antiepileptic, applications, approach, approaches, barrierin, biosimilar, biosimilarstwo, bispecific, blood, brain, briefmicrobubbles,


Best articles

'New' FDA delivers in 2003

View more

2003 approvals: a year of innovation and upward trends

View more

A bridge between academia and the drug discovery pipeline

View more

A solid view of GPCRs

View more

Adipocyte metabolism

View more

Aventis-Sanofi: a good R&D merger?

View more

BACE failures lower AD expectations, again

View more

Betting on biogenerics

View more

Biodegradable multi-drug dispenser

View more

Birds of a feather...

View more

Blocking without obstruction

View more

Certolizumab pegol

View more
SHOW MORE ARTICLES

Challenges and opportunities in animal drug development: a regulatory perspective

View more

Correction: Cox-2 and beyond: Approaches to prostagland in inhibition in human disease

View more

David Liu

View more

Eight steps to silence

View more

Emerging unscathed?

View more

Employment trends in 2003

View more

Engaging biotechnology companies in the development of innovative solutions for diseases of poverty

View more

Engineering a smoother ride

View more

Exercising self-control

View more

Family traits

View more

FDA approves first-in-class SYK inhibitor

View more

Genome-based pharmacogenetics and the pharmaceutical industry

View more

Comments

No comments ... Be the first to comment!